Human anti-Human Immunodeficiency Virus type 1, anti-Human Immunodeficiency Virus type 2, and anti-Treponema pallidum antibodies (HIV/Syphilis Ab)

Human anti-Human Immunodeficiency Virus type 1, anti-Human Immunodeficiency Virus type 2, and anti-Treponema pallidum antibodies are a group of host-produced immunoglobulins that serve as diagnostic biomarkers for infection (CDC, 2021). These antibodies are generated by the immune system's B-cells in response to specific antigens from the HIV-1 and HIV-2 viruses and the bacterium Treponema pallidum, the causative agent of syphilis (PubMed, 2020). In clinical practice, these antibodies are typically detected using multiplexed immunoassay platforms, which allow for the simultaneous screening of multiple sexually transmitted infections from a single patient sample (WHO, 2019). These antibodies are not therapeutic targets; instead, they indicate the presence of pathogens that are treated with specific medications, such as antiretroviral drugs for HIV and penicillin for syphilis (StatPearls, 2023). The clinical utility of these antibodies is primarily in diagnosis and epidemiological monitoring, though their detection is subject to a “window period” where an infected individual may test negative before seroconversion occurs (PubMed, 2021). Furthermore, diagnostic challenges include potential cross-reactivity and the persistence of antibodies even after successful treatment, particularly in the case of syphilis (CDC, 2021).

Other names

HIV-1/2 and Syphilis antibodiesAnti-HIV and anti-Treponema antibodiesHIV/Syphilis serologyAnti-HIV-1/2 and anti-TP antibodies

Not applicable as these are diagnostic analytes/biomarkers of infection rather than therapeutic targets.